The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.
New portable biosensor could revolutionize heart failure screening at home
Heart failure is a leading cause of death worldwide and is especially fatal for people who don’t have access to medical facilities. So, a team
August 19, 2024